1268521-85-2

Basic information

• Product Name: Cyclobutanecarboxylic acid, 3-hydroxy-, trans-
• Synonyms: Cyclobutanecarboxylic acid, 3-hydroxy-, trans-;(1r,3r)-3-hydroxycyclobutane-1-carboxylic acid;trans-3-Hydroxycyclobutanecarboxylic acid;(1R,3R)-3-hydroxycyclobutanecarboxylic acid
• CAS NO: 1268521-85-2
• Molecular Formula: C5H8O3
• Molecular Weight: 116
• Mol File: 1268521-85-2.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: Cyclobutanecarboxylic acid, 3-hydroxy-, trans-(CAS DataBase Reference)
• NIST Chemistry Reference: Cyclobutanecarboxylic acid, 3-hydroxy-, trans-(1268521-85-2)
• EPA Substance Registry System: Cyclobutanecarboxylic acid, 3-hydroxy-, trans-(1268521-85-2)

Safety Data

• Hazardous Substances Data: 1268521-85-2(Hazardous Substances Data)

Usage

General Description

Cyclobutanecarboxylic acid, 3-hydroxy-, trans- is a chemical compound that falls under the category of carboxylic acids. It is a trans isomer of 3-hydroxycyclobutanecarboxylic acid and has a molecular formula of C5H8O3. Cyclobutanecarboxylic acid, 3-hydroxy-, trans- is used in various research and chemical processes and has potential applications in pharmaceuticals, agrochemicals, and material science.

Upstream product

• 695-95-4 methyl 3-oxocyclobutanecarboxylate 
• 4934-99-0 methylester of 3-hydroxycyclobutane-1-carboxylic acid 
• 480449-99-8 3-hydroxycyclobutylcarboxylic acid benzyl ester 

Downstream Products

• 1089340-69-1 3-hydroxy-N-methylcyclobutanecarboxamide 

Relevant articles and documents

Method for synthesizing trans-3-hydroxy cyclobutyl formic acid

The invention belongs to the field of organic synthesis and discloses a method for synthesizing trans-3-hydroxy cyclobutyl formic acid. The method comprises the following steps: by using an appropriate reducing agent, reducing 3-carbonyl-cyclobutane formate (C1-C6 alkyl ester) into single trans-3-hydroxy cyclobutyl formic ether in an efficient stereoselectivity manner, and further performing a Mitsunobu reaction and hydrolysis, thereby obtaining single trans-3-hydroxy cyclobutyl formic acid. The method provided by the invention is high in synthesis method raw material availability, mild in reaction condition, good in stereoselectivity and relatively high in yield; in addition, aftertreatment and purification are both easy to operate, and the method is applicable to industrial amplified production.

DIAMINE DERIVATIVES

A compound represented by formula (1):Q1-Q2-To-N(R1) -Q3-N(R2)-T1-Q4 [wherein R1 and R2 are hydrogen atoms or the like; Q1 is a saturated or unsaturated, 5- or 6- membered cyclic hydrocarbon group which may be substituted, or the like; Q2 is a single bond or the like; Q3 represents the following group: (wherein Q5 is an alkylene group having 1 to 8 carbon atoms, or the like); and T0 and T1 are carbonyl groups or the like], a salt thereof, a solvate thereof, or an N-oxide thereof. The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after artificial valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

DIAMINE DERIVATIVES

A compound represented by the general formula (1):Q1-Q2-T0-N(R1)-Q3-N(R2)-T1-Q4 wherein R1 and R2 are hydrogen atoms or the like; Q1 is a saturated or unsaturated, 5- or 6- membered cyclic hydrocarbon group which may be substituted, or the like; Q2 is a single bond or the like; Q3 is a group in which Q5 is an alkylene group having 1 to 8 carbon atoms, or the like; and T0 and T1 are carbonyl groups or the like; a salt thereof, a solvate thereof, or an N-oxide thereof. The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.